D. E. Shaw & Co., Inc. Eli Lilly & CO Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 411,700 shares of LLY stock, worth $362 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

411,700

Holding current value

$362 Million

% of portfolio

0.34%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $132 Million - $164 Million	170,860 Added 72.03%	408,082 $362 Million
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $7.36 Million - $9.23 Million	10,158 Added 4.47%	237,222 $215 Million
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $38.4 Million - $51.4 Million	-64,866 Reduced 22.22%	227,064 $177 Million
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $102 Million - $120 Million	193,556 Added 196.76%	291,930 $170 Million
Q3 2023 Nov 14, 2023	SELL	$434.7 - $599.3 $291 Million - $401 Million	-669,445 Reduced 87.19%	98,374 $52.8 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $180 Million - $240 Million	512,076 Added 200.23%	767,819 $360 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $20.2 Million - $23.8 Million	65,174 Added 34.2%	255,743 $87.8 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $24.2 Million - $28.2 Million	75,387 Added 65.45%	190,569 $69.7 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $23.8 Million - $27.1 Million	80,335 Added 230.54%	115,182 $37.2 Million
Q2 2022 Aug 15, 2022	SELL	$278.73 - $327.27 $26 Million - $30.5 Million	-93,305 Reduced 72.81%	34,847 $11.3 Million
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $60 Million - $74.6 Million	-255,860 Reduced 66.63%	128,152 $36.7 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $17.9 Million - $22.2 Million	79,737 Added 26.21%	384,012 $106 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $55.2 Million - $67.9 Million	249,141 Added 451.88%	304,275 $70.3 Million
Q2 2021 Aug 16, 2021	SELL	$180.55 - $233.54 $82.9 Million - $107 Million	-458,906 Reduced 89.27%	55,134 $12.7 Million
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $1.7 Million - $2.25 Million	13,047 Added 2.6%	514,040 $86.8 Million
Q3 2020 Nov 16, 2020	BUY	$146.22 - $169.13 $54 Million - $62.5 Million	369,633 Added 281.39%	500,993 $74.2 Million
Q2 2020 Aug 14, 2020	BUY	$136.42 - $164.18 $12.1 Million - $14.6 Million	88,779 Added 208.49%	131,360 $21.6 Million
Q1 2020 May 15, 2020	SELL	$119.05 - $147.35 $3.98 Million - $4.93 Million	-33,457 Reduced 44.0%	42,581 $5.91 Million
Q4 2019 Feb 14, 2020	SELL	$106.92 - $132.43 $64.3 Million - $79.6 Million	-601,210 Reduced 88.77%	76,038 $9.99 Million
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $17.1 Million - $18.6 Million	-160,461 Reduced 19.15%	677,248 $75.7 Million
Q2 2019 Aug 14, 2019	BUY	$110.79 - $129.32 $2.65 Million - $3.09 Million	23,885 Added 2.93%	837,709 $92.8 Million
Q1 2019 May 15, 2019	SELL	$111.31 - $131.02 $42.4 Million - $49.8 Million	-380,469 Reduced 31.86%	813,824 $106 Million
Q4 2018 Feb 14, 2019	SELL	$105.9 - $118.64 $28.7 Million - $32.2 Million	-271,142 Reduced 18.5%	1,194,293 $138 Million
Q3 2018 Nov 14, 2018	SELL	$85.86 - $107.31 $41.8 Million - $52.3 Million	-487,282 Reduced 24.95%	1,465,435 $157 Million
Q2 2018 Aug 14, 2018	SELL	$75.7 - $86.88 $47.3 Million - $54.3 Million	-624,489 Reduced 24.23%	1,952,717 $167 Million
Q1 2018 May 15, 2018	BUY	$74.21 - $87.6 $87.7 Million - $103 Million	1,181,307 Added 84.63%	2,577,206 $199 Million
Q4 2017 Feb 14, 2018	SELL	$81.94 - $87.89 $3.56 Million - $3.82 Million	-43,448 Reduced 3.02%	1,395,899 $118 Million
Q3 2017 Nov 14, 2017	BUY	$77.07 - $85.54 $111 Million - $123 Million	1,439,347	1,439,347 $123 Million

Others Institutions Holding LLY

# of Institutions

4,121

Shares Held

740M

Call Options Held

8.26M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $835B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account